These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 8695276)

  • 1. In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells.
    Luparello C; Del Rosso M
    Eur J Cancer; 1996 Apr; 32A(4):702-7. PubMed ID: 8695276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
    Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
    DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
    Fischer K; Lutz V; Wilhelm O; Schmitt M; Graeff H; Heiss P; Nishiguchi T; Harbeck N; Kessler H; Luther T; Magdolen V; Reuning U
    FEBS Lett; 1998 Oct; 438(1-2):101-5. PubMed ID: 9821967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
    Levenson AS; Kwaan HC; Svoboda KM; Weiss IM; Sakurai S; Jordan VC
    Br J Cancer; 1998 Jul; 78(1):88-95. PubMed ID: 9662256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of cell-associated plasminogen activation catalyzed by urokinase-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87).
    Longstaff C; Merton RE; Fabregas P; Felez J
    Blood; 1999 Jun; 93(11):3839-46. PubMed ID: 10339491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
    Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
    Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
    Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
    Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase induces receptor mediated brain tumor cell migration and invasion.
    MacDonald TJ; DeClerck YA; Laug WE
    J Neurooncol; 1998 Dec; 40(3):215-26. PubMed ID: 10066093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
    Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
    Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells.
    Hjertner O; Qvigstad G; Hjorth-Hansen H; Seidel C; Woodliff J; Epstein J; Waage A; Sundan A; Börset M
    Br J Haematol; 2000 Jun; 109(4):815-22. PubMed ID: 10929035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitronectin binding to urokinase receptor in human breast cancer.
    Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
    Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
    Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
    Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
    Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
    Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases.
    Guerrero J; Santibañez JF; González A; Martínez J
    Exp Cell Res; 2004 Jan; 292(1):201-8. PubMed ID: 14720519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
    Huang S; New L; Pan Z; Han J; Nemerow GR
    J Biol Chem; 2000 Apr; 275(16):12266-72. PubMed ID: 10766865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S; Vrhovec I; Svetic B; Cufer T
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.